Key Players in the Chronic Urticaria Market
Major pharmaceutical companies active in the chronic urticaria field include Sanofi-Aventis, Merck, UCB, Regeneron, Roche, Principia Biopharma, Novartis, AstraZeneca and Kyowa Kirin.

Overview of the chronic urticaria treatment market
(Albany, USA)- DelveInsight's "Chronic Urticaria – Market Insights, Epidemiology, and Market Forecast – 2032" report provides comprehensive insights into the disease, including historical and projected epidemiology, market dynamics, and treatment status in the US, EU5 (Germany, France, Italy, Spain, UK), and Japan.

The report provides a detailed analysis of current clinical practice, new drugs, market share by therapy, and forecast market size segmented by seven major markets (7MM) from 2019 to 2032. It also highlights current treatment approaches, key market drivers and barriers, identifies unmet needs, and unlocks potential opportunities in the setting of chronic urticaria.

? Request a free sample @Market forecast for chronic urticaria

Key Highlights of the Chronic Urticaria Market Report

• According to DelveInsight, the chronic urticaria market is expected to grow at a steady CAGR until 2032.
  
  
• Major players include Sanofi-Aventis, Merck, UCB, Regeneron, Roche, Principia Biopharma, Novartis, AstraZeneca, Kyowa Kirin, etc.
  
  
• Key pipeline and marketed therapeutics expected to shape the market include fexofenadine, omalizumab, desloratadine, levocetirizine, dupilumab, rilzabrutinib, remibrutinib, benralizumab, regelizumab, and others.
  
  

Recent Clinical and Regulatory Developments

• March 2025– Novartis shared results from a 52-week, multicenter, randomized, double-blind, placebo-controlled basket study.Remibrutinib (LOU064)Adults with CIndU not adequately controlled with H1 antihistamines.
  
  
• February 2025– Celldex Therapeutics announced Phase 3 results.Valzolvolimab(EMBARQ-CSU1), a monoclonal antibody for CSU patients unresponsive to H1 antihistamines.
  
  
• January 2025– Novartis presented the results of a real-world study evaluating safety and efficacy.Xolair® (omalizumab)Chinese adolescents with CSU.
  
  
• March 2025– Jiangsu Hanso Pharmaceutical announced the results of its Phase 1/2 trial.HS-10561In CSU patients.
  
  
• December 2024– Incyte released phase 2 dataPovorcitinibA placebo-controlled dose-ranging study in patients with CSU.
  
  
• November 2024– Jasper Therapeutics announced results from a Phase 1b/2a dose-escalation study.BurkitlimabIn CIndU patients.
  
  
• May 2024– A 52-week study confirmed long-term safety.Remibrutinib, strengthening its promise as a next-generation treatment option.
  
  
• February 2024– SanofiRilzabrutinibIt provided positive Phase II data for CSU, signaling a potential therapeutic breakthrough.
  
  

Chronic Urticaria: Disease Overview

Chronic urticaria is a persistent skin condition that causes itchy, red, swollen welts (hives) that last for more than six weeks. It is subdivided into:

• Chronic spontaneous urticaria (CSU)– Occurs without a known trigger.
  
  
• Chronic Induced Urticaria (CIndU)– Triggered by certain physical stimuli such as cold, heat, or pressure.
  
  

The exact cause is unknown, but is commonly associated with autoimmune dysfunction, allergies, infections, and stress. Diagnosis is based on clinical evaluation and medical history, and first-line treatment typically involves second-generation antihistamines. Biologics and BTK inhibitors are being explored for more resistant cases.

Rising incidence of autoimmune and allergic diseases, coupled with innovations in biologics and immunotherapy, are driving market growth.

? Explore global treatment algorithms and patient trends @Chronic Urticaria Treatment Market

Market Outlook: Chronic Urticaria

This section analyzes current and emerging therapies and evaluates them by cost, mechanism of action, market penetration, patient population and expected competition. The outlook highlights key trends, expected launches and competitive benchmarking through impactful visualizations in tables and graphs.

DelveInsight predicts that significant market shifts will occur by 7MM between 2019-2032.

Epidemiology of chronic urticaria

This part of the report analyzes the historical, current, and projected patient population across 7MM based on literature review and expert insights, providing a clear picture of prevalence, diagnosis, and disease dynamics.

? learn more @ Prevalence and trends of chronic urticaria

Drug uptake and pipeline development

This section focuses on the adoption trajectory of both approved and pipeline drugs, assessing market penetration, adoption drivers and sales potential.

Major commercially available treatments:

• Fexofenadine (Allegra® – ​​Sanofi)– Second generation H1 antihistamines, widely prescribed for CU.
  
  
• Desloratadine (Clarinex® – Merck Co.)– Known for its effectiveness and minimal sedation in CU management.
  
  
• Xolair® (omalizumab – Roche/Novartis)– Innovative biologics used in refractory CSU cases.
  
  

Major new treatments:

• Rilzabrutinib (Sanofi/Principia Biopharma)– BTK inhibitors targeting immune cells in hives.
  
  
• Remibrutinib (Novartis)– Investigational BTK inhibitors with promising long-term efficacy and safety data.
  
  

? Request a complete pipeline and trial landscape @Clinical trials for chronic urticaria

Drug evaluation and competitive environment

Key companies innovating in this space include sanofi-aventis, Merck Co., UCB, Regeneron, Roche, Principia Biopharma, Novartis, AstraZeneca, and Kyowa Kirin, among others, developing next-generation therapies to fill unmet needs in the management of CU.

? Stay up to date on upcoming treatments @Chronic urticaria drug market

Chronic Urticaria Report Insights

1. Prevalence and epidemiological trends
   
   
2. Market forecast and growth factors
   
   
3. Competitive Landscape and Pipeline Analysis
   
   
4. Current treatments and treatment algorithms
   
   
5. Market Challenges and Unmet Needs
   
   
6. Current status of emerging drugs
   
   
7. Key Market Opportunities
   
   

Table of Contents (Summary)

1. Key Insights
   
   
2. executive summary
   
   
3. Competitive Intelligence
   
   
4. Market Overview
   
   
5. Background of the disease
   
   
6. The patient journey
   
   
7. Epidemiology
   
   
8. Current Treatment
   
   
9. Unmet needs
   
   
10. Primary Treatment Endpoint
    
    
11. Over-the-counter treatments
    
    
12. New Pipeline
    
    
13. 7MM Market Analysis
    
    
14. Attribute analysis
    
    
15. Market forecast (2019-2032)
    
    
16. Access and reimbursement status
    
    
17. KOL Perspective
    
    
18. Market Drivers
    
    
19. Market Barriers
    
    
20. appendix
    
    
21. DelveInsight Features
    
    
22. Disclaimer
    
    

About DelveInsight

DelveInsight is a leading life sciences market research and consulting firm, providing customized research and syndicated reports across the entire healthcare value chain. We are focused on providing deep, actionable insights into the evolving biopharmaceutical landscape.